ppharmПедиатрическая фармакологияPediatric pharmacology1727-57762500-3089Издательство «ПедиатрЪ»10.15690/pf.v15i1.1846ppharm-1596Research ArticleВАКЦИНАЦИЯ В СОВРЕМЕННОМ МИРЕVACCINATIONОбзор вакцинации против папилломавирусной инфекции в миреOverview of the Global Vaccination against Human Papillomavirushttps://orcid.org/0000-0002-2209-7531Намазова-БарановаЛ. С.Namazova-BaranovaLeyla S.

Москва

Moscow

https://orcid.org/0000-0002-3598-9600ЧемакинаД. С.ChemakinaDaria S.

Чемакина Дарья Сергеевна - младший научный сотрудник отдела стандартизации и клинической фармакологии НИИ педиатрии НМИЦ здоровья детей.

119991, Москва, Ломоносовский пр-т, д. 2, стр. 1, тел.: +7 (499) 134-03-92

Moscow

daria06ch@gmail.comhttps://orcid.org/0000-0001-7398-0562ВишнёваЕ. А.VishnevaElena A.

Москва

Moscow

https://orcid.org/0000-0003-0797-5612ФедосеенкоМ. В.FedoseenkoMarina V.

Москва

Moscow

https://orcid.org/0000-0002-3678-7939СелимзяноваЛ. Р.SelimzianovaLilia R.

Москва

Moscow

Национальный медицинский исследовательский центр здоровья детей; Российский национальный исследовательский медицинский университет им. Н.И. ПироговаРоссияNational Medical Research Center of Children’s Health; Pirogov Russian National Research Medical UniversityRussian FederationНациональный медицинский исследовательский центр здоровья детей; Первый Московский государственный медицинский университет имени И.М. СеченоваРоссияNational Medical Research Center of Children’s Health; I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)Russian FederationНациональный медицинский исследовательский центр здоровья детейРоссияNational Medical Research Center of Children’s HealthRussian FederationНациональный медицинский исследовательский центр здоровья детейРоссияNational Medical Research Center of Children’s Health;Russian Federation2018270220181518085Copyright © Намазова-Баранова Л.С., Чемакина Д.С., Вишнёва Е.А., Федосеенко М.В., Селимзянова Л.Р., 20182018Намазова-Баранова Л.С., Чемакина Д.С., Вишнёва Е.А., Федосеенко М.В., Селимзянова Л.Р.Namazova-Baranova L.S., Chemakina D.S., Vishneva E.A., Fedoseenko M.V., Selimzianova L.R.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pedpharma.ru/jour/article/view/1596

В статье представлены сведения о текущем состоянии проблемы профилактики папилломавирусной инфекции среди населения разных стран мира. Описаны пути включения прививки против вируса папилломы человека в государственные национальные программы иммунизации. Кроме того, отражены возможные способы финансирования внедряемого проекта для каждого региона мира. Результаты внедренной иммунизации против папилломавирусной инфекции в странах-пионерах позволили сделать выводы не только о текущем состоянии вакцинации населения этих государств, но также о результатах ее эффективности.

Конфликт интересов

Конфликт интересов

Л

Л.С. Намазова-Баранова — получение исследовательских грантов от фармацевтических компаний Пьер Фабр, Genzyme Europe B. V., ООО «Астра зенека Фармасьютикалз», Gilead/PRA «Фармасьютикал Рисерч Ассошиэйтс СиАйЭс», «Bionorica», Teva Branded Pharmaceutical products R&D, Inc/ООО «ППД Девелопмент (Смоленск)», «Сталлержен С. А.»/«Квинтайлс ГезмбХ» (Австрия). М. В. Федосеенко — получение гонораров от компании Sanofi, Pfizer за чтение лекций.

The article presents an overview of the current status of the vaccination against Human Papillomavirus (HPV) in the world. It describes different approaches to expanding the coverage with HPV vaccination at different national levels by inclusion of the vaccine in National Immunization Programmes. Moreover, the principal ways of project financing in different regions of the world are referred to. The results of the implemented vaccination against HPV in the pioneer countries provide the conclusions on the current situation of HPV vaccination in the world and strategies demonstrating its effectiveness.

вакцинациявирус папилломы человекаВПЧнациональная программа иммунизацииvaccinationHuman PapillomavirusHPVNational immunization programМСД, компанияReferencesmsfaccess.org [Internet]. Médecins Sans Frontières [Doctors without borders]. Human Papillomavirus Vaccines (HPV) WHO recommendations & general information. 2014. [cited 2017 Jun 13]. Available from: https://www.msfaccess.org/sites/default/files/MSF_assets/Vaccines/Docs/VAC_report_ProductCardHPV_ENG_2014.pdfmsfaccess.org [Internet]. Médecins Sans Frontières [Doctors without borders]. Human Papillomavirus Vaccines (HPV) WHO recommendations & general information. 2014. [cited 2017 Jun 13]. Available from: https://www.msfaccess.org/sites/default/files/MSF_assets/Vaccines/Docs/VAC_report_ProductCardHPV_ENG_2014.pdfwho.int [Internet]. WHO vaccine-preventable diseases: monitoring system. 2017 global summary [cited 2017 Jun 13]. Available from: http://apps.who.int/immunization_monitoring/globalsummary/scheduleswho.int [Internet]. WHO vaccine-preventable diseases: monitoring system. 2017 global summary [cited 2017 Jun 13]. Available from: http://apps.who.int/immunization_monitoring/globalsummary/schedulesРегиональные бюро ВОЗ. [WHO regional offices. (In Russ).] Доступно по: http://www.who.int/about/regions/ru/ Ссылка активна на 29.09.2017.Региональные бюро ВОЗ. [WHO regional offices. (In Russ).] Доступно по: http://www.who.int/about/regions/ru/ Ссылка активна на 29.09.2017.Альянс ГАВИ. ВОЗ. [GAVI Alliance. (In Russ).] Доступно по: http://www.euro.who.int/ru/about-us/partners/global-healthpartnerships/gavi-alliance. Ссылка активна на 29.09.2017.Альянс ГАВИ. ВОЗ. [GAVI Alliance. (In Russ).] Доступно по: http://www.euro.who.int/ru/about-us/partners/global-healthpartnerships/gavi-alliance. Ссылка активна на 29.09.2017.gavi.org [Internet]. GAVI: The Vaccine Alliance. Country Hub [cited 2017 Aug 9]. Available from: http://www.gavi.org/country/gavi.org [Internet]. GAVI: The Vaccine Alliance. Country Hub [cited 2017 Aug 9]. Available from: http://www.gavi.org/country/gavi.org [Internet]. GAVI: The Vaccine Alliance. HPV. Countries approved for support 2017 [cited 2017 Aug 9]. Available from: http://www.gavi.org/results/countries-approved-for-support/gavi.org [Internet]. GAVI: The Vaccine Alliance. HPV. Countries approved for support 2017 [cited 2017 Aug 9]. Available from: http://www.gavi.org/results/countries-approved-for-support/Franceschi S, Chantal Umulisa M, Tshomo U, et al. Urine testing to monitor the impact of HPV vaccination in Bhutan and Rwanda. Int J Cancer. 2016;139(3):518–526. doi: 10.1002/ijc.30092.Franceschi S, Chantal Umulisa M, Tshomo U, et al. Urine testing to monitor the impact of HPV vaccination in Bhutan and Rwanda. Int J Cancer. 2016;139(3):518–526. doi: 10.1002/ijc.30092.Ngabo F, Franceschi S, Baussano I, et al. Human papillomavirus infection in Rwanda at the moment of implementation of a national HPV vaccination programme. BMC Infect Dis. 2016;16:225. doi: 10.1186/s12879-016-1539-6.Ngabo F, Franceschi S, Baussano I, et al. Human papillomavirus infection in Rwanda at the moment of implementation of a national HPV vaccination programme. BMC Infect Dis. 2016;16:225. doi: 10.1186/s12879-016-1539-6.Bruni L, Barrionuevo-Rosas L, Albero G, et al. ICO Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases in Rwanda [Internet]. Summary Report 27 July 2017 [cited 2017 Oct 9]. Available from: http://www.hpvcentre.net/statistics/reports/RWA.pdfBruni L, Barrionuevo-Rosas L, Albero G, et al. ICO Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases in Rwanda [Internet]. Summary Report 27 July 2017 [cited 2017 Oct 9]. Available from: http://www.hpvcentre.net/statistics/reports/RWA.pdfUNICEF Supply Division. Human Papillomavirus Vaccine Supply & Demand Update. 2015 [Internet]. [cited 2017 Aug 10]. Available from: https://www.unicef.org/supply/files/Human_Papillomavirus_Vaccine(HPV)_Supply_and_Demand_Update_-_July_2015.pdfUNICEF Supply Division. Human Papillomavirus Vaccine Supply & Demand Update. 2015 [Internet]. [cited 2017 Aug 10]. Available from: https://www.unicef.org/supply/files/Human_Papillomavirus_Vaccine(HPV)_Supply_and_Demand_Update_-_July_2015.pdfnci.nih.gov [Internet]. President’s cancer panel annual report. Part 4. Increasing global HPV vaccination*. 2013 [cited 2017 Aug 10]. Available from: https://deainfo.nci.nih.gov/advisory/pcp/annualreports/hpv/Part4.htm#ref16nci.nih.gov [Internet]. President’s cancer panel annual report. Part 4. Increasing global HPV vaccination*. 2013 [cited 2017 Aug 10]. Available from: https://deainfo.nci.nih.gov/advisory/pcp/annualreports/hpv/Part4.htm#ref16paho.org [Internet]. About the Pan American Health Organization (PAHO) [cited 2017 Aug 10]. Available from: http://www.paho.org/hq/index.php?option=com_content&view=article&id=91&Itemid=220&lang=enpaho.org [Internet]. About the Pan American Health Organization (PAHO) [cited 2017 Aug 10]. Available from: http://www.paho.org/hq/index.php?option=com_content&view=article&id=91&Itemid=220&lang=enSmith LM, Strumpf EC, Kaufman JS, et al. The early benefits of human papillomavirus vaccination on cervical dysplasia and anogenital warts. Pediatrics. 2015;135(5):E1131–E1140. doi: 10.1542/peds.2014-2961.Smith LM, Strumpf EC, Kaufman JS, et al. The early benefits of human papillomavirus vaccination on cervical dysplasia and anogenital warts. Pediatrics. 2015;135(5):E1131–E1140. doi: 10.1542/peds.2014-2961.Kim J, Bell C, Sun MG, et al. Effect of human papillomavirus vaccination on cervical cancer screening in Alberta. CMAJ. 2016;188(12):E281–E288. doi: 10.1503/cmaj.151528.Kim J, Bell C, Sun MG, et al. Effect of human papillomavirus vaccination on cervical cancer screening in Alberta. CMAJ. 2016;188(12):E281–E288. doi: 10.1503/cmaj.151528.Ogilvie GS, Naus M, Money DM, et al. Reduction in cervical intraepithelial neoplasia in young women in British Columbia after introduction of the HPV vaccine: an ecological analysis. Int J Cancer. 2015;137(8):1931–1937. doi: 10.1002/ijc.29508.Ogilvie GS, Naus M, Money DM, et al. Reduction in cervical intraepithelial neoplasia in young women in British Columbia after introduction of the HPV vaccine: an ecological analysis. Int J Cancer. 2015;137(8):1931–1937. doi: 10.1002/ijc.29508.Markowitz LE, Hariri S, Lin C, et al. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003–2010. J Infect Dis. 2013;208(3):385–393. doi: 10.1093/infdis/jit192.Markowitz LE, Hariri S, Lin C, et al. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003–2010. J Infect Dis. 2013;208(3):385–393. doi: 10.1093/infdis/jit192.Hariri S, Bennett NM, Niccolai LM, et al. Reduction in HPV 16/18-associated high grade cervical lesions following HPV vaccine introduction in the United States 2008–2012. Vaccine. 2015;33(13):1608–1613. doi: 10.1016/j.vaccine.2015.01.084.Hariri S, Bennett NM, Niccolai LM, et al. Reduction in HPV 16/18-associated high grade cervical lesions following HPV vaccine introduction in the United States 2008–2012. Vaccine. 2015;33(13):1608–1613. doi: 10.1016/j.vaccine.2015.01.084.Powell SE, Hariri S, Steinau M, et al. Impact of human papillomavirus (HPV) vaccination on HPV 16/18-related prevalence in precancerous cervical lesions. Vaccine. 2012;31(1):109–113. doi: 10.1016/j.vaccine.2012.10.092.Powell SE, Hariri S, Steinau M, et al. Impact of human papillomavirus (HPV) vaccination on HPV 16/18-related prevalence in precancerous cervical lesions. Vaccine. 2012;31(1):109–113. doi: 10.1016/j.vaccine.2012.10.092.Hariri S, Unger ER, Powell SE, et al. The HPV vaccine impact monitoring project (HPV-IMPACT): assessing early evidence of vaccination impact on HPV-associated cervical cancer precursor lesions. Cancer Causes Control. 2012;23(2):281–288. doi: 10.1007/s10552-011-9877-6.Hariri S, Unger ER, Powell SE, et al. The HPV vaccine impact monitoring project (HPV-IMPACT): assessing early evidence of vaccination impact on HPV-associated cervical cancer precursor lesions. Cancer Causes Control. 2012;23(2):281–288. doi: 10.1007/s10552-011-9877-6.Bruni L, Barrionuevo-Rosas L, Albero G, et al. ICO Information Centre on HPV and Cancer (HPV Information Centre). HumanBruni L, Barrionuevo-Rosas L, Albero G, et al. ICO Information Centre on HPV and Cancer (HPV Information Centre). HumanPapillomavirus and Related Diseases in Libya [Internet]. Summary Report 27 July 2017 [cited 2017 Oct 9]. Available from: http://www.hpvcentre.net/statistics/reports/LBY.pdf.Papillomavirus and Related Diseases in Libya [Internet]. Summary Report 27 July 2017 [cited 2017 Oct 9]. Available from: http://www.hpvcentre.net/statistics/reports/LBY.pdf.Ben Khaial F, Bodalal Z, Elramli A, et al. Cervical cancer in northeastern Libya: 2000–2008. J Obstet Gynaecol. 2014;34(6):523–526. doi: 10.3109/01443615.2014.914478.Ben Khaial F, Bodalal Z, Elramli A, et al. Cervical cancer in northeastern Libya: 2000–2008. J Obstet Gynaecol. 2014;34(6):523–526. doi: 10.3109/01443615.2014.914478.Hussein WM, Anwar WA, Attaleb M, et al. A review of the infection-associated cancers in North African countries. Infect Agent Cancer. 2016;11:35. doi: 10.1186/s13027-016-0083-8.Hussein WM, Anwar WA, Attaleb M, et al. A review of the infection-associated cancers in North African countries. Infect Agent Cancer. 2016;11:35. doi: 10.1186/s13027-016-0083-8.Bruni L, Barrionuevo-Rosas L, Albero G, et al. ICO Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases in Bahrain [Internet]. Summary Report 27 July 2017 [cited 2017 Oct 9]. Available from: http://www.hpvcentre.net/statistics/reports/BHR.pdfBruni L, Barrionuevo-Rosas L, Albero G, et al. ICO Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases in Bahrain [Internet]. Summary Report 27 July 2017 [cited 2017 Oct 9]. Available from: http://www.hpvcentre.net/statistics/reports/BHR.pdfHajjaj AA, Senok AC, Al-Mahmeed AE, et al. Human papillomavirus infection among women attending health facilities in the Kingdom of Bahrain. Saudi Med J. 2006;27(4):487–491.Hajjaj AA, Senok AC, Al-Mahmeed AE, et al. Human papillomavirus infection among women attending health facilities in the Kingdom of Bahrain. Saudi Med J. 2006;27(4):487–491.Moosa K, Alsayyad AS, Quint W, et al. An epidemiological study assessing the prevalence of human papillomavirus types in women in the Kingdom of Bahrain. BMC Cancer. 2014;14:905. doi: 10.1186/1471-2407-14-905.Moosa K, Alsayyad AS, Quint W, et al. An epidemiological study assessing the prevalence of human papillomavirus types in women in the Kingdom of Bahrain. BMC Cancer. 2014;14:905. doi: 10.1186/1471-2407-14-905.Bhatia R, Kavanagh K, Cubie HA, et al. Use of HPV testing for cervical screening in vaccinated womenInsights from the SHEVa (Scottish HPV Prevalence in Vaccinated Women) study. Int J Cancer. 2016;138(12):2922–2931. doi: 10.1002/ijc.30030.Bhatia R, Kavanagh K, Cubie HA, et al. Use of HPV testing for cervical screening in vaccinated womenInsights from the SHEVa (Scottish HPV Prevalence in Vaccinated Women) study. Int J Cancer. 2016;138(12):2922–2931. doi: 10.1002/ijc.30030.Mesher D, Panwar K, Thomas SL, et al. Continuing reductions in HPV 16/18 in a population with high coverage of bivalent HPV vaccination in England: an ongoing cross-sectional study. BMJ Open. 2016;6(2):e009915. doi: 10.1136/bmjopen-2015-009915.Mesher D, Panwar K, Thomas SL, et al. Continuing reductions in HPV 16/18 in a population with high coverage of bivalent HPV vaccination in England: an ongoing cross-sectional study. BMJ Open. 2016;6(2):e009915. doi: 10.1136/bmjopen-2015-009915.Pollock KG, Kavanagh K, Potts A, et al. Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland. Br J Cancer. 2014;111(9):1824–1830. doi: 10.1038/bjc.2014.479.Pollock KG, Kavanagh K, Potts A, et al. Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland. Br J Cancer. 2014;111(9):1824–1830. doi: 10.1038/bjc.2014.479.Canvin M, Sinka K, Hughes G, Mesher D. Decline in genital warts diagnoses among young women and young men since the introduction of the bivalent HPV (16/18) vaccination programme in England: an ecological analysis. Sex Transm Infect. 2017;93(2):125–128. doi: 10.1136/sextrans-2016-052626.Canvin M, Sinka K, Hughes G, Mesher D. Decline in genital warts diagnoses among young women and young men since the introduction of the bivalent HPV (16/18) vaccination programme in England: an ecological analysis. Sex Transm Infect. 2017;93(2):125–128. doi: 10.1136/sextrans-2016-052626.Luostarinen T, Apter D, Dillner J, et al. Vaccination protects against invasive HPV-associated cancers. Int J Cancer. 2018. [Epub ahead of print] doi: 10.1002/ijc.31231.Luostarinen T, Apter D, Dillner J, et al. Vaccination protects against invasive HPV-associated cancers. Int J Cancer. 2018. [Epub ahead of print] doi: 10.1002/ijc.31231.Tshomo U, Franceschi S, Dorji D, et al. Human papillomavirus infection in Bhutan at the moment of implementation of a national HPV vaccination programme. BMC Infect Dis. 2014;14(1):408. doi: 10.1186/1471-2334-14-408.Tshomo U, Franceschi S, Dorji D, et al. Human papillomavirus infection in Bhutan at the moment of implementation of a national HPV vaccination programme. BMC Infect Dis. 2014;14(1):408. doi: 10.1186/1471-2334-14-408.Osborne SL, Tabrizi SN, Brotherton JML, et al. Assessing genital human papillomavirus genoprevalence in young Australian women following the introduction of a national vaccination program. Vaccine. 2015;33(1):201–208. doi: 10.1016/j.vaccine.2014.10.045.Osborne SL, Tabrizi SN, Brotherton JML, et al. Assessing genital human papillomavirus genoprevalence in young Australian women following the introduction of a national vaccination program. Vaccine. 2015;33(1):201–208. doi: 10.1016/j.vaccine.2014.10.045.Ali H, Donovan B, Wand H, et al. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ. 2013;346:f2032. doi: 10.1136/bmj.f2032.Ali H, Donovan B, Wand H, et al. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ. 2013;346:f2032. doi: 10.1136/bmj.f2032.Garland SM, Kjaer SK, Munoz N, et al. Impact and effectiveness of the quadrivalent human papillomavirus vaccine: a systematic review of 10 years of real-world experience. Clin Infect Dis. 2016;63(4):519–527. doi: 10.1093/cid/ciw354.Garland SM, Kjaer SK, Munoz N, et al. Impact and effectiveness of the quadrivalent human papillomavirus vaccine: a systematic review of 10 years of real-world experience. Clin Infect Dis. 2016;63(4):519–527. doi: 10.1093/cid/ciw354.Gertig DM, Brotherton JM, Budd AC, et al. Impact of a populationbased HPV vaccination program on cervical abnormalities: a data linkage study. BMC Med. 2013;11:227. doi: 10.1186/1741-7015- 11-227.Gertig DM, Brotherton JM, Budd AC, et al. Impact of a populationbased HPV vaccination program on cervical abnormalities: a data linkage study. BMC Med. 2013;11:227. doi: 10.1186/1741-7015- 11-227.Chow EP, Machalek DA, Tabrizi SN, et al. Quadrivalent vaccinetargeted human papillomavirus genotypes in heterosexual men after the Australian female human papillomavirus vaccination programme: a retrospective observational study. Lancet Infect Dis. 2017;17(1):68–77. doi: 10.1016/S1473-3099(16)30116-5.Chow EP, Machalek DA, Tabrizi SN, et al. Quadrivalent vaccinetargeted human papillomavirus genotypes in heterosexual men after the Australian female human papillomavirus vaccination programme: a retrospective observational study. Lancet Infect Dis. 2017;17(1):68–77. doi: 10.1016/S1473-3099(16)30116-5.Machalek DA, Chow EP, Garland SM, et al. Human papillomavirus prevalence in unvaccinated heterosexual males following a National Female Vaccination Program. J Infect Dis. 2016;215(2):202–208. doi: 10.1093/infdis/jiw530.Machalek DA, Chow EP, Garland SM, et al. Human papillomavirus prevalence in unvaccinated heterosexual males following a National Female Vaccination Program. J Infect Dis. 2016;215(2):202–208. doi: 10.1093/infdis/jiw530.

The authors declare that there are no conflicts of interest present.